Substance use and menopausal symptoms among people with and without HIV in the US, 2008-2020.

ABSTRACT

OBJECTIVE: The aim of the study is to assess associations between substance use and menopausal symptoms among US people living with and without HIV in a longitudinal cohort. METHODS: We analyzed self-reported menopausal symptoms and substance use from biannual Women's Interagency HIV Study (WIHS) visits from 2008-2020. Substance use since the last visit or lifetime cumulative use included tobacco, alcohol, marijuana, crack/cocaine, and opioids. Logistic regression quantified associations between each substance use and menopausal symptom frequency (vasomotor, mood, and musculoskeletal), adjusting for other substance use, HIV status, demographics, comorbidities, and trauma. RESULTS: A total of 1,949 participants contributed early perimenopausal, late perimenopausal, or postmenopausal study visits. Across reproductive-aging stages, based on menstrual history, and among participants with and without HIV, participants reported frequent vasomotor (range 22-43%), mood (18-28%), and musculoskeletal (25-34%) symptoms. Many reported ever using tobacco (72%), heavy alcohol (75%), marijuana (73%), crack (50%), and opioids (31%). Current heavy alcohol use (odds ratio [OR] 1.22; 95% confidence interval [CI] 1.10-1.37), cumulative marijuana use (OR 1.15, 95% CI 1.01-1.32), and cumulative tobacco use (OR 1.06, 95% CI 1.01-1.12) were associated with a higher frequency of vasomotor symptoms; current heavy alcohol use (OR 1.20, 95% CI 1.04-1.39) and current opioid use (OR 1.13; 95% CI 1.01-1.25) were associated with mood symptoms; and current opioid use (OR 1.11, 95% CI 1.00-1.23) was associated with musculoskeletal symptoms. All other associations were found to be null. CONCLUSIONS: Current and prior substance use may independently affect symptoms experienced during the menopausal transition and may indicate potential to benefit from additional intervention and referral to menopause specialty care.